New Parkinson's drug enters human testing for first time
NCT ID NCT06809400
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 36 times
Summary
This early-stage study tests a new drug called LY4006896 in healthy volunteers and people with Parkinson's disease. The main goal is to check if the drug is safe and how the body processes it. Around 127 participants will receive either the drug or a placebo by IV. This is a first step to see if the drug is worth testing further for Parkinson's.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PARKINSON DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aqualane Clinical Research
RECRUITINGNaples, Florida, 34105, United States
Contact Phone: •••-•••-••••
Contact
-
Charter Research
RECRUITINGOrlando, Florida, 32803, United States
Contact Phone: •••-•••-••••
Contact
-
Charter Research
RECRUITINGThe Villages, Florida, 32162-2698, United States
Contact Phone: •••-•••-••••
Contact
-
Collaborative Neuroscience Network - CNS
RECRUITINGLos Alamitos, California, 90720, United States
-
Collaborative Neuroscience Network - CNS
RECRUITINGLos Alamitos, California, 90720, United States
Contact Phone: •••-•••-••••
Contact Phone: •••-•••-••••
Contact
Contact
-
Evergreen Health Research
NOT_YET_RECRUITINGKirkland, Washington, 98034, United States
Contact Phone: •••-•••-••••
Contact
-
Inland Northwest Research
NOT_YET_RECRUITINGSpokane, Washington, 99202, United States
Contact Phone: •••-•••-••••
Contact
-
K2 Medical Research, LLC
COMPLETEDMaitland, Florida, 32751, United States
-
K2 Medical Research, LLC
RECRUITINGThe Villages, Florida, 32159, United States
Contact Phone: •••-•••-••••
Contact
-
Oita University Hospital
RECRUITINGYufu, 879-5593, Japan
Contact Phone: •••-•••-••••
Contact
-
P-One Clinic
RECRUITINGHachiōji, 192-0071, Japan
Contact Phone: •••-•••-••••
Contact
-
PPD Development, LP
RECRUITINGAustin, Texas, 78744, United States
Contact Phone: •••-•••-••••
Contact
-
Progressive Medical Research
RECRUITINGPort Orange, Florida, 32127, United States
Contact Phone: •••-•••-••••
Contact
-
QUEST Research Institute
RECRUITINGFarmington Hills, Michigan, 48334, United States
Contact Phone: •••-•••-••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
LY4006896
What this could lead to
If successful, this could point toward a new treatment that slows or modifies Parkinson's disease progression.
What could go wrong
This is a very early Phase 1 trial focused on safety, not effectiveness. The drug may not work or could have side effects. Results may not apply to all Parkinson's patients.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.